title: Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats.
abstract: This study was designed to investigate the role of eicosanoids, thromboxane A2 (TXA2) and prostacyclin (PGI2) as well as their relationship with endothelin-1 (ET-1) in the pathogenesis of renal parenchymal hypertension. Uremic rats were prepared by renal mass ablation and compared with sham-operated controls. The stable metabolites of TXA2 (TXB2) and PGI2 (6-keto-PGF1alpha) and immunoreactive ET-1 concentrations were measured by specific RIAs in biological fluids and in vascular and renal tissues. To investigate the functional role of TXA2 in the progression of hypertension and renal failure, a group of uremic rats were treated with ridogrel (25 mg/kg/day), a TXA2 synthase inhibitor and receptor antagonist. Renal preproET-1 expression was assessed by Northern blot analysis. Systolic blood pressure (SBP), serum creatinine and proteinuria were found to be higher in uremic rats as compared to sham-operated controls (P < 0.01). TXB2 and ET-1 concentrations were increased in blood vessels, the renal cortex and in urine (P < 0.05). 6-keto-PGF1alpha concentrations were also increased in blood vessels and the renal cortex but decreased in urine (P < 0.05). Ridogrel significantly lowered SBP and proteinuria (P < 0.05) and blunted the increase of serum creatinine. Treatment with ridogrel resulted in a marked fall in vascular, renal and urine TXA2 concentrations, while ET-1 and 6-keto-PGF1alpha concentrations remained unchanged. The preproET-1 expression was higher in uremic rats than in the controls and was unaffected by ridogrel. These results suggest that TXA2 is involved in the pathogenesis of hypertension and renal failure progression in rats with subtotal 5/6 nephrectomy and that this effect is independent of the ET-1 system.
authors.affiliation: Research Centre and Division of Nephrology, CHUQ, L'Hôtel-Dieu de Québec Hospital and Department of Medicine, Laval University, Quebec, Canada. richard.lariviere@crhdq.ulaval.ca
authors.forename: Richard
authors.initials: R
authors.lastname: Larivière
authors.forename: Claudia
authors.initials: C
authors.lastname: Moreau
authors.forename: Marie-Eve
authors.initials: ME
authors.lastname: Rodrigue
authors.forename: Marcel
authors.initials: M
authors.lastname: Lebel
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D004195:Disease Models, Animal; D018450:Disease Progression; D015777:Eicosanoids / Q000494:pharmacology / Q000502:physiology; D019332:Endothelin-1 / Q000502:physiology*; D011464:Epoprostenol / Q000494:pharmacology / Q000502:physiology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D051437:Renal Insufficiency / Q000503:physiopathology*; D013928:Thromboxane A2 / Q000494:pharmacology / Q000502:physiology*; D013997:Time Factors; D014511:Uremia / Q000503:physiopathology*
chemical_list: D015777:Eicosanoids; D019332:Endothelin-1; D013928:Thromboxane A2; D011464:Epoprostenol